RBC Capital on Biogen (BIIB): 'Competition from assets such as trontinemab remains years away, and not a threat this decade most likely'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $220.00 price target on Biogen (NASDAQ: BIIB).The analyst comments "This ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
